These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7967232)

  • 1. Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs.
    Shirakura S; Higo K; Takeda M; Karasawa A
    Jpn J Pharmacol; 1994 Jun; 65(2):93-8. PubMed ID: 7967232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs.
    Higo K; Karasawa A
    Jpn J Pharmacol; 1993 Dec; 63(4):521-3. PubMed ID: 8121085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate against 9,11-dideoxy- 9 alpha, 11 alpha-epoxymethano-prostaglandin F2 alpha-induced sudden death in guinea-pigs and rats.
    Shirakura S; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1242-5. PubMed ID: 1815523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
    Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
    Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effect of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate on collagen-induced coronary ischemia in guinea-pigs.
    Kawakage M; Shirakura S; Karasawa A; Takeda M; Miki I; Ishii A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1246-50. PubMed ID: 1815524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations.
    Karasawa A; Shirakura S; Higo K; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1237-41. PubMed ID: 1815522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of KW-3635 on the diuretic action of furosemide in rats].
    Kawakage M; Ishihara N; Karasawa A; Kase H
    Nihon Yakurigaku Zasshi; 1993 Jan; 101(1):33-8. PubMed ID: 8444379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a thromboxane A2-receptor antagonist, a thromboxane synthetase inhibitor and aspirin on prostaglandin I2 production in endothelium-intact and -injured aorta of guinea pigs.
    Higo K; Karasawa A
    Jpn J Pharmacol; 1994 Dec; 66(4):471-9. PubMed ID: 7723224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of KW-3635, a specific thromboxane A2-receptor antagonist, on experimental glomerulonephritis in mice.
    Kawakage M; Sato K; Karasawa A
    Jpn J Pharmacol; 1994 Jun; 65(2):163-6. PubMed ID: 7967228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets.
    Miki I; Kishibayashi N; Nonaka H; Ohshima E; Takami H; Obase H; Ishii A
    Jpn J Pharmacol; 1992 Jul; 59(3):357-64. PubMed ID: 1434130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of KW-3635, a thromboxane A2 antagonist, on arachidonic acid-induced transient cerebral ischemia in dogs.
    Satoh H; Kobayashi T; Higo K; Karasawa A
    Jpn J Pharmacol; 1994 May; 65(1):45-50. PubMed ID: 8089929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury.
    Terashita Z; Imura Y; Kawamura M; Kato K; Nishikawa K
    Thromb Res; 1995 Mar; 77(5):411-21. PubMed ID: 7778056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of KW-3635, a specific thromboxane A2-receptor antagonist, on the development of lupus nephritis in NZB x NZW F1 mice.
    Kawakage M; Mizumoto H; Nukui E; Sato S; Karasawa A
    Jpn J Pharmacol; 1993 Dec; 63(4):433-8. PubMed ID: 8121078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.
    Imura Y; Kiyota Y; Nagai Y; Nishikawa K; Terashita Z
    Thromb Res; 1995 Jul; 79(1):95-107. PubMed ID: 7495108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in activities of thromboxane A2 receptor antagonists in smooth muscle cells.
    Miki I; Kase H; Ishii A
    Eur J Pharmacol; 1992 Oct; 227(2):199-204. PubMed ID: 1426029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel thromboxane A2 receptor antagonist KW-3635 abolishes the cyclic flow reduction in the canine carotid artery.
    Higo K; Karasawa A
    Biol Pharm Bull; 1994 Jul; 17(7):902-6. PubMed ID: 8000373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y; Asai F; Wada K; Nakashima M
    Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.